Overview
APRE market data
Price History
APRE price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.93 Diluted earnings per share over the trailing twelve months.
- Beta
- -1.27 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -4,409.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.55 – $1.79 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $8M · P/B 0.45 · P/S 28.17.
Company News
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3Benzinga · Aug 13, 2026, 12:55 PM
8-K filing — Aprea Therapeutics, Inc. (APRE)SEC EDGAR · Aug 12, 2026, 12:35 PM
Aprea Therapeutics Q2 EPS $(0.07) Beats $(0.23) EstimateBenzinga · Aug 12, 2026, 12:32 PM
Aprea Therapeutics Announces ACESOT-1051 Enrollment Is Accelerating; Clinical Data Presentation Planned For Q4 2026Benzinga · Jul 30, 2026, 12:02 PM
Aprea Therapeutics Presents Early Results From Its First-In-Human Phase 1 Trial Of WEE1 Inhibitor APR-1051 In Participants With Advanced Solid TumorsBenzinga · Jun 1, 2026, 12:08 PM